Background: Empagliflozin is a selective sodium–glucose cotransporter-2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus. Its intestinal permeability presents an opportunity for improving oral drug delivery through lipid-based nanocarriers. The present study aimed to develop, screen, and characteriz...
Satya Prakash, Garima Gupta, Mohammad Rashid et al.· Adolescência e Saúde· 0 citations
Current preclinical and emerging evidence indicate that the modulation of interconnected pathological pathways, including mitochondrial dysfunction, insulin resistance, and neuroinflammation, may lead to improved therapeutic outcomes, and the incorporation of early diagnostic biomarkers in conjunction with the use of m...
Lalit Parihar, A. Singh, Sanjar Alam· Current Pharmacogenomics and...· 0 citations
The study highlights the biphasic biological behavior of p-cymene, characterized by non-toxic or mildly stimulatory effects at low concentrations and pronounced cytotoxicity at higher doses.
Lalit Parihar, Sanjar Alam, A. Singh· International Journal of Dru...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.